Polycythemia Vera (PV)

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers

Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Potential Biological and Physiological Determinants for Exercice in Patients With Polycythemia Vera

MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial

Managed Access Programs for INC424, Ruxolitinib

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms

EVAluation of Erythrocytosis PRospEctive Cohort STudy

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

A Study to Evaluate P1101 in Japanese PV Patients

Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients

Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms

Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.